New
HealthMore in Health→
PET-Guided Care Points to Chemotherapy Reduction in HER2 Breast Cancer
Key Takeaways
- PHERGain tested a PET-guided strategy to adapt treatment and potentially omit chemotherapy in selected early HER2-positive breast cancers.
- After median 5.6 years of follow-up, five-year invasive disease-free survival was 89.5% in the PET-guided group.
- A selected subgroup of PET responders achieving pathological complete response without chemotherapy had reported five-year invasive disease-free survival of 92.4%.
- The results are from a non-comparative phase 2 trial and support further validation rather than broad treatment replacement.
DE
DT Editorial Team··via nature.com